Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Gao, Rong ^a   Cheng, Jianhua ^a   Fan, Chunlei ^b   Shi, Xiaofeng ^c,d   Cao, Yuan ^e   Sun, Bo ^a   Ding, Huiguo ^b   Hu, Chengjin ^e   Dong, Fangting ^a   Yan, Xianzhong ^a  

^a NATIONAL CENTER OF BIOMEDICAL ANALYSIS   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d THE SECOND AFFILIATED HOSPITAL OF CHONGQING MEDICAL UNIVERSITY   (China)

^e JINAN MILITARY GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

BLOOD; CARCINOMA, HEPATOCELLULAR; CASE CONTROL STUDY; CELL TRANSFORMATION; CLUSTER ANALYSIS; COMPLICATION; DISEASE COURSE; HEPATITIS; HUMAN; LIVER DISEASE; LIVER NEOPLASMS; METABOLISM; METABOLOME; METABOLOMICS; PATHOLOGY; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC;

BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DISEASE PROGRESSION; HEPATITIS; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; METABOLIC NETWORKS AND PATHWAYS; METABOLOME; METABOLOMICS; ROC CURVE;

EID: 84949591106     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18175     Document Type: Article

References (40)

1. Lanaya, H. et al. EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. Nat. Cell Biol. 16, 972-981 (2014).
2. Dhanasekaran, R., Limaye, A. & Cabrera, R. Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics. Hepat. Med. 4, 19-37 (2012).
3. Flores, A. & Marrero, J. A. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin. Med. Insights Oncol. 8, 71-76 (2014).
4. Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030-3044 (2006).
5. Farrell, G. C. et al. Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements. J. Gastroenterol. Hepatol. 25, 657-663 (2010).
6. Yuen, M. F., Hou, J. L. & Chutaputti, A. Hepatocellular carcinoma in the Asia pacific region. J. Gastroenterol. Hepatol. 24, 346-353 (2009).
7. Luo, R. H., Zhao, Z. X., Zhou, X. Y., Gao, Z. L. & Yao, J. L. Risk factors for primary liver carcinoma in Chinese population. World J. Gastroenterol. 11, 4431-4434 (2005).
8. Gao, H. et al. Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma. Clin. Cancer Res. 20, 6418-28 (2014).
9. Locasale, J. W., Vander Heiden, M. G. & Cantley, L. C. Rewiring of glycolysis in cancer cell metabolism. Cell Cycle 9, 4253-4253 (2014).
10. Beyoglu, D. et al. Tissue metabolomics of hepatocellular carcinoma: tumor energy metabolism and the role of transcriptomic classification. Hepatology 58, 229-238 (2013).
11. Fitian, A. I. et al. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Liver Int. 34, 1428-1444 (2014).
12. Zeng, J. et al. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry. J. Proteome Res. 13, 3420-3431 (2014).
13. Wang, X. et al. Urine metabolomics analysis for biomarker discovery and detection of jaundice syndrome in patients with liver disease. Mol. Cell Proteomics 11, 370-380 (2012).
14. Ressom, H. W. et al. Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal. Chim. Acta 743, 90-100 (2012).
15. Gao, H. et al. Application of 1H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 100, 782-785 (2009).
16. Nahon, P. et al. Identification of serum proton NMR metabolomic fingerprints associated with hepatocellular carcinoma in patients with alcoholic cirrhosis. Clin. Cancer Res. 18, 6714-6722 (2012).
17. Huang, Q. et al. Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics. Cancer Res. 73, 4992-5002 (2013).
18. Tan, Y. et al. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Mol. Cell Proteomics 11, M111 010694 (2012).
19. Chen, T. et al. Random forest in clinical metabolomics for phenotypic discrimination and biomarker selection. Evid. Based Complement. Alternat. Med. 2013, 298183 (2013).
20. Zhang, Y., Zhang, H., Elizabeth, A. & Liu, X. Q. Epidemiology of hepatitis B and associated liver diseases in china. Chin. Med. Sci. J. 27, 243-248 (2013).
21. Xia, J. & Wishart, D. S. Web-based inference of biological patterns, functions and pathways from metabolomic data using Metabo Analyst. Nat. Protoc. 6, 743-760 (2011).
22. Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell 21, 297-308 (2012).
23. Kroemer, G. & Pouyssegur, J. Tumor cell metabolism: cancer's Achilles' heel. Cancer cell 13, 472-482 (2008).
24. Wang, X., Zhang, A. & Sun, H. Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma. Hepatology 57, 2072-2077 (2013).
25. Shao, Y. et al. Development of Urinary Pseudotargeted LC-MS-Based Metabolomics Method and Its Application in Hepatocellular Carcinoma Biomarker Discovery. J. Proteome Res. 14, 906-916 (2015).
26. Koppenol, W. H., Bounds, P. L. & Dang, C. V. Otto Warburg's contributions to current concepts of cancer metabolism. Nat. Rev. Cancer 11, 325-337 (2011).
27. Pollard, P. J. et al. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet. 14, 2231-2239 (2005).
28. Shimizu, T. et al. Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas. J. Gastroenterol. 49, 1324-1332 (2014).
29. Lee, S. et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer cell 8, 155-167 (2005).
30. Balamurugan, K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int. J Cancer doi: 10.1002/ijc.29519 (2015).
31. Icard, P., Poulain, L. & Lincet, H. Understanding the central role of citrate in the metabolism of cancer cells. Biochim. Biophys. Acta 1825, 111-116 (2012).
32. Chen, J. Q. & Russo, J. Dysregulation of glucose transport, glycolysis, TCA cycle and glutaminolysis by oncogenes and tumor suppressors in cancer cells. Biochim. Biophys. Acta 1826, 370-384 (2012).
33. Daye, D. & Wellen, K. E. Metabolic reprogramming in cancer: unraveling the role of glutamine in tumorigenesis. Semin. Cell Dev. Biol. 23, 362-369 (2012).
34. Cairns, R. A., Harris, I. S. & Mak, T. W. Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95 (2011).
35. Qiu, Y. et al. A distinct metabolic signature of human colorectal cancer with prognostic potential. Clin. Cancer Res. 20, 2136-2146 (2014).
36. Hu, J. et al. Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat. Biotechnol. 31, 522-529 (2013).
37. Vander Heiden, M. G. et al. Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science 329, 1492-1499 (2010).
38. Chen, T. et al. Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular. Mol. Cell Proteomics 10, M110.004945 (2011).
39. Chen, S. et al. Pseudotargeted metabolomics method and its application in serum biomarker discovery for hepatocellular carcinoma based on ultra high-performance liquid chromatography/triple quadrupole mass spectrometry. Anal. Chem. 85, 8326-8333 (2013).
40. Muir, K. et al. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma. Cancer Res. 73, 4722-4731 (2013).